A Study to Investigate the Effect of Multiple Doses of Danoprevir/Ritonavir (DNV/RTV) on the Pharmacokinetics (PK) of Escitalopram (ESC) and S-Demethylcitalopram (S-DCT) in Healthy Subjects

Trial Profile

A Study to Investigate the Effect of Multiple Doses of Danoprevir/Ritonavir (DNV/RTV) on the Pharmacokinetics (PK) of Escitalopram (ESC) and S-Demethylcitalopram (S-DCT) in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2016

At a glance

  • Drugs Danoprevir (Primary) ; Ritonavir (Primary) ; Escitalopram
  • Indications Generalised anxiety disorder; Hepatitis C; HIV infections; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Social phobia
  • Focus Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 16 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Planned End Date changed from 31 Aug 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top